Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …

Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …

Background Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis,
which are typically transmitted via respiratory droplets, are leading causes of invasive …

Background Concerns have been raised regarding a potential surge of COVID-19 in
pregnancy, secondary to the rising numbers of COVID-19 in the community, easing of societal …

Background We describe post-COVID symptomatology in a non-hospitalised, national sample
of adolescents aged 11–17 years with PCR-confirmed SARS-CoV-2 infection compared …

Background The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key
serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7), …

Background A rapid increase in cases due to the SARS-CoV-2 Omicron (B.1.1.529) variant
in highly vaccinated populations has raised concerns about the effectiveness of current …

Background Efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) was
inferred before licensure from an aggregate correlate of protection established for the seven-valent …

Background Pneumococcal conjugate vaccines (PCVs) have substantially reduced the
incidence of invasive pneumococcal disease caused by vaccine serotypes; however, …

The epidemiology of invasive meningococcal disease continues to change rapidly, even in
the three years since the first Meningococcal Exchange Meeting in 2008. Control of disease …